Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response
Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response
复制标题
DOI：
10.1111/bjh.12847
复制
发表时间：
2014-07-01
影响因子：
6.5
通讯作者：
Wagner, John E., Jr.
中科院分区：
文献类型：
--
作者：
Dietz, Andrew C.;DeFor, Todd E.;Wagner, John E., Jr.
供体源性骨髓增生异常综合征/急性白血病（DD-MDS/AL）是异基因造血干细胞（HSC）移植的一种罕见的危及生命的并发症。然而，尚不清楚该风险是否因 HSC 来源而异。因此，我们评估了 2390 名移植患者中 DD-MDS/AL 的发生率。中位随访时间为 7.1 年 (1-20.8)，骨髓受者中 DD-MDS/AL 的发生率为 0.53%（95% 置信区间 (CI)，0.01-1.41%]、0.56%（95% CI，0.01-1.36%）和 0.56%（95% CI，0.01-1.10%）分别为（n = 1117）、外周血（n = 489）和脐带血（UCB，n = 784），虽然 UCB 和外周血受者的随访时间较短，但迄今为止，HSC 来源之间的 DD-MDS/AL 发生率相似。
Donor-derived myelodysplastic syndrome/acute leukaemia (DD-MDS/AL) is a rare life-threatening complication of allogeneic haematopoietic stem cell (HSC) transplantation. However, it is unknown whether the risk differs by HSC source. Therefore, we evaluated the incidence of DD-MDS/AL in 2390 engrafted patients. With a median follow-up of 7.1 years (1-20.8), the incidence of DD-MDS/AL was 0.53% (95% confidence interval (CI), 0.01-1.41%], 0.56% (95% CI, 0.01-1.36%) and 0.56% (95% CI, 0.01-1.10%) in recipients of bone marrow (n = 1117), peripheral blood (n = 489) and umbilical cord blood (UCB, n = 784), respectively. While follow-up is shorter in recipients of UCB and peripheral blood, incidence of DD-MDS/AL is, thus far, similar between HSC sources.